Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$957.76+5.36 (+0.56%)
Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –
Regeneron Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Regeneron Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $16.90B, up 18.6% year over year. For fiscal 2025 it was $14.34B, up 1.0% from the year before. Over ten years it grew 13.3% a year on average. The highest annual figure on record is $16.07B in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.34B | +1.0% |
| FY2024 | Dec 31, 2024 | $14.20B | +8.3% |
| FY2023 | Dec 31, 2023 | $13.12B | +7.8% |
| FY2022 | Dec 31, 2022 | $12.17B | -24.3% |
| FY2021 | Dec 31, 2021 | $16.07B | +89.1% |
| FY2020 | Dec 31, 2020 | $8.50B | +29.6% |
| FY2019 | Dec 31, 2019 | $6.56B | +27.4% |
| FY2018 | Dec 31, 2018 | $5.15B | -12.4% |
| FY2017 | Dec 31, 2017 | $5.87B | +20.8% |
| FY2016 | Dec 31, 2016 | $4.86B | +18.4% |
| FY2015 | Dec 31, 2015 | $4.10B | +45.5% |
| FY2014 | Dec 31, 2014 | $2.82B | +34.0% |
| FY2013 | Dec 31, 2013 | $2.10B | +52.7% |
| FY2012 | Dec 31, 2012 | $1.38B | +209.2% |
| FY2011 | Dec 31, 2011 | $445.82M | -2.9% |
| FY2010 | Dec 31, 2010 | $459.07M | +21.0% |
| FY2009 | Dec 31, 2009 | $379.27M | +59.1% |
| FY2008 | Dec 31, 2008 | $238.46M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.12B | +36.3% |
| Q2 FY2026 | Jun 30, 2026 | $4.29B | +16.7% |
| Q1 FY2026 | Mar 31, 2026 | $3.61B | +19.0% |
| Q4 FY2025 | Dec 31, 2025 | $3.88B | +2.5% |
| Q3 FY2025 | Sep 30, 2025 | $3.75B | +0.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.68B | +3.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.03B | -3.7% |
| Q4 FY2024 | Dec 31, 2024 | $3.79B | +10.3% |
| Q3 FY2024 | Sep 30, 2024 | $3.72B | +10.6% |
| Q2 FY2024 | Jun 30, 2024 | $3.55B | +12.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.15B | -0.5% |
| Q4 FY2023 | Dec 31, 2023 | $3.43B | +0.6% |
| Q3 FY2023 | Sep 30, 2023 | $3.36B | +14.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.16B | +10.5% |
| Q1 FY2023 | Mar 31, 2023 | $3.16B | +6.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.41B | -31.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.94B | -15.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.86B | -44.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.97B | +17.3% |
| Q4 FY2021 | Dec 31, 2021 | $4.95B | +104.4% |
| Q3 FY2021 | Sep 30, 2021 | $3.45B | +50.5% |
| Q2 FY2021 | Jun 30, 2021 | $5.14B | +163.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.53B | +38.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.42B | +30.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.29B | +31.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.95B | +23.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.83B | +33.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.86B | -3.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.74B | +4.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.58B | -1.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.37B | -9.2% |
| Q4 FY2018 | Dec 31, 2018 | $1.93B | +21.8% |
| Q3 FY2018 | Sep 30, 2018 | $1.66B | +10.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.61B | +9.4% |
| Q1 FY2018 | Mar 31, 2018 | $1.51B | +14.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.58B | +29.0% |
| Q3 FY2017 | Sep 30, 2017 | $1.50B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.47B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.32B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.23B | – |
See a number that looks wrong?